Matthew N. Meriggioli

3.8k total citations · 2 hit papers
61 papers, 2.6k citations indexed

About

Matthew N. Meriggioli is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Matthew N. Meriggioli has authored 61 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Neurology, 15 papers in Genetics and 14 papers in Molecular Biology. Recurrent topics in Matthew N. Meriggioli's work include Myasthenia Gravis and Thymoma (31 papers), Peripheral Neuropathies and Disorders (23 papers) and Neurogenetic and Muscular Disorders Research (13 papers). Matthew N. Meriggioli is often cited by papers focused on Myasthenia Gravis and Thymoma (31 papers), Peripheral Neuropathies and Disorders (23 papers) and Neurogenetic and Muscular Disorders Research (13 papers). Matthew N. Meriggioli collaborates with scholars based in United States, France and Italy. Matthew N. Meriggioli's co-authors include Donald B. Sanders, Julie Rowin, Bellur S. Prabhakar, Jian Rong Sheng, Muthusamy Thiruppathi, Balaji Ganesh, Sue E. Leurgans, Jeffrey T. Guptill, Liangcheng Li and Premkumar Christadoss and has published in prestigious journals such as The Journal of Immunology, Neurology and Cancer Research.

In The Last Decade

Matthew N. Meriggioli

60 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

2009 610 citations Matthew N. Meriggioli, Donald B. Sanders The Lancet Neurology profile →
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

2021 173 citations Jerry R. Mendell, Samiah Al-Zaidy et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew N. Meriggioli United States	27	1.7k	479	437	308	263	61	2.6k
Masakatsu Motomura Japan	25	2.2k 1.3×	439 0.9×	769 1.8×	153 0.5×	252 1.0×	142	3.2k
Amelia Evoli Italy	28	2.8k 1.6×	570 1.2×	235 0.5×	180 0.6×	331 1.3×	69	3.1k
Kumaran Deiva France	27	1.2k 0.7×	208 0.4×	463 1.1×	259 0.8×	81 0.3×	97	2.4k
Emanuela Bartoccioni Italy	23	1.1k 0.6×	396 0.8×	294 0.7×	180 0.6×	140 0.5×	43	1.6k
Premkumar Christadoss United States	35	2.2k 1.3×	817 1.7×	299 0.7×	867 2.8×	74 0.3×	106	3.2k
Catherine Keohane Ireland	21	361 0.2×	199 0.4×	340 0.8×	235 0.8×	211 0.8×	64	1.8k
Yael Hacohen United Kingdom	26	1.7k 1.0×	353 0.7×	277 0.6×	155 0.5×	127 0.5×	95	2.4k
Konstantinos Lazaridis Greece	19	701 0.4×	249 0.5×	483 1.1×	129 0.4×	153 0.6×	52	1.7k
Alberto Vogrig France	25	1.8k 1.0×	400 0.8×	258 0.6×	105 0.3×	46 0.2×	77	2.4k
Bishan Radotra India	17	309 0.2×	175 0.4×	336 0.8×	360 1.2×	293 1.1×	93	1.8k

Countries citing papers authored by Matthew N. Meriggioli

Since Specialization

Citations

This map shows the geographic impact of Matthew N. Meriggioli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew N. Meriggioli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew N. Meriggioli more than expected).

Fields of papers citing papers by Matthew N. Meriggioli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew N. Meriggioli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew N. Meriggioli. The network helps show where Matthew N. Meriggioli may publish in the future.

Co-authorship network of co-authors of Matthew N. Meriggioli

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew N. Meriggioli. A scholar is included among the top collaborators of Matthew N. Meriggioli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew N. Meriggioli. Matthew N. Meriggioli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mendell, Jerry R., Samiah Al-Zaidy, Kelly J. Lehman, et al.. (2021). Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurology. 78(7). 834–834. 173 indexed citations breakdown →

Mendell, Jerry R., Richard S. Finkel, Eugenio Mercuri, et al.. (2021). Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA) (2301). Neurology. 96(15_supplement). 2 indexed citations

Finkel, Richard S., John Day, Basil T. Darras, et al.. (2019). Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG) (P1.6-059). Neurology. 92(15_supplement). 2 indexed citations

Muntoni, Francesco, Giovanni Baranello, Claudio Bruno, et al.. (2019). Study Design of STR1VE-EU, a Phase 3 Trial of AVXS-101 Gene-Replacement Therapy (GRT) in Patients With Spinal Muscular Atrophy Type 1 (SMA1) in Europe. Neuropediatrics. 2 indexed citations

Guptill, Jeffrey T., Madhu Soni, & Matthew N. Meriggioli. (2015). Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 13(1). 118–131. 49 indexed citations

Thiruppathi, Muthusamy, Jian Rong Sheng, Liangcheng Li, Bellur S. Prabhakar, & Matthew N. Meriggioli. (2014). Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. Journal of Autoimmunity. 52. 64–73. 41 indexed citations

Benatar, Michael, Donald B. Sanders, Ted M. Burns, et al.. (2012). Recommendations for myasthenia gravis clinical trials. Muscle & Nerve. 45(6). 909–917. 114 indexed citations

Meriggioli, Matthew N. & Donald B. Sanders. (2012). Muscle autoantibodies in myasthenia gravis: beyond diagnosis?. Expert Review of Clinical Immunology. 8(5). 427–438. 121 indexed citations

Brown, Charlotte A., Juergen Scharner, Kevin J. Felice, et al.. (2011). Novel and recurrent EMD mutations in patients with Emery–Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. Journal of Human Genetics. 56(8). 589–594. 26 indexed citations

10.

Sheng, Jian Rong, et al.. (2010). In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor. Experimental Neurology. 225(2). 320–327. 12 indexed citations

11.

Scharner, Juergen, Charlotte A. Brown, Matthew Bower, et al.. (2010). Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Human Mutation. 32(2). 152–167. 55 indexed citations

12.

Sheng, Jian Rong, et al.. (2009). Acetylcholine receptor‐α subunit expression in myasthenia gravis: A role for the autoantigen in pathogenesis?. Muscle & Nerve. 40(2). 279–286. 8 indexed citations

13.

Meriggioli, Matthew N.. (2009). Myasthenia Gravis with Anti-Acetylcholine Receptor Antibodies. Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences. 26. 94–108. 39 indexed citations

14.

Meriggioli, Matthew N. & Donald B. Sanders. (2009). Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology. 8(5). 475–490. 610 indexed citations breakdown →

15.

Sheng, Jian Rong, et al.. (2008). Regulation of Apoptosis and Caspase-8 Expression in Neuroblastoma Cells by Isoforms of the IG20 Gene. Cancer Research. 68(18). 7352–7361. 22 indexed citations

16.

Sheng, Jian Rong, Liangcheng Li, Balaji Ganesh, et al.. (2006). Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. The Journal of Immunology. 177(8). 5296–5306. 67 indexed citations

17.

Rowin, Julie, Matthew N. Meriggioli, Erdem Tüzün, Sue E. Leurgans, & Premkumar Christadoss. (2004). Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 63(12). 2390–2392. 57 indexed citations

18.

Meriggioli, Matthew N. & Donald B. Sanders. (1999). Conduction block and continuous motor unit activity in chronic acquired demyelinating polyneuropathy. Muscle & Nerve. 22(4). 532–537. 4 indexed citations

19.

Rowin, Julie & Matthew N. Meriggioli. (1999). Complex repetitive discharges: Cause or effect of neurogenic muscle hypertrophy?. Muscle & Nerve. 22(11). 1603–1606. 13 indexed citations

20.

Meriggioli, Matthew N., Julie Rowin, & Donald B. Sanders. (1999). Distinguishing clinical and electrodiagnostic features of X-linked bulbospinal neuronopathy. Muscle & Nerve. 22(12). 1693–1697. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact